

Table S1. Baseline Characteristics of U.S. Adults Meeting the Definition for Hypertension and Recommended Antihypertensive Medication According to the 2017 ACC/AHA Guideline and the JNC8 Guideline Based on the 2013–2016 PINNACLE Data.

| | 2017 ACC/AHA Guideline | | JNC8 Guidelines | | Difference (2017 ACC/AHA, But Not JNC8) | |
|--|----------------------------|--|----------------------------|--|---|--|
| Characteristics | Hypertension (N = 5027961) | Recommended Antihypertensive Medication (N = 4266118) | Hypertension (N = 4521272) | Recommended Antihypertensive Medication (N = 3734134) | Hypertension (N = 506689) | Recommended Antihypertensive Medication (N = 531984) |
| History of Hypertension | 75.4% (3793378/5027961) | 78.3% (3339820/4266118) | 83.9% (3793378/4521272) | 80.5% (3006240/3734134) | 0.0% (0/506689) | 62.7% (333580/531984) |
| On Antihypertensive Medications | 66.9% (3365371/5027961) | 78.8% (3363807/4266118) | 74.2% (3353197/4521272) | 89.8% (3353197/3734134) | 2.4% (12174/506689) | 2.0% (10610/531984) |
| Number of BP Measurements Used | | | | | | |
| $Mean \pm SD (N)$ | 2.0±0.1 (5027961) | 2.0±0.1 (4266118) | 2.0±0.1 (4521272) | 2.0±0.1 (3734134) | 2.0±0.1 (506689) | 2.0±0.1 (531984) |
| Median (Q1,Q3) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) |
| Range (Min,Max) | (2.0,6.0) | (2.0,6.0) | (2.0,6.0) | (2.0,6.0) | (2.0,6.0) | (2.0,5.0) |
| Ejection Fraction ≤40 | 9.9% (190324/1919712) | 9.8% (172856/1758731) | 9.6% (175670/1834413) | 9.4% (150237/1596142) | 17.2% (14654/85299) | 13.9% (22619/162589) |
| Ejection Fraction ≤40 among those without hypertension and on antihypertensive meds | 5.1% (12187/238602) | 4.6% (10841/237256) | 0.4% (933/227348) | 0.4% (933/227348) | 100.0% (11254/11254) | 100.0% (9908/9908) |

ACC=American College of Cardiology, AHA=American Heart Association; JNC7= Seventh Joint National Committee (JNC7); ASCVD= atherosclerotic cardiovascular disease; CVD= cardiovascular disease; SD=standard deviation; Q=quartile; min=minimum; max=maximum; US=United States, N=number

Table S2. Baseline Characteristics of U.S. Adults Meeting the Definition for Hypertension and Recommended Antihypertensive Medication According to the 2017 ACC/AHA Guideline and the JNC7 Guideline Based on the 2013–2016 PINNACLE Data.

| | 2017 ACC/AHA Guideline | | JNC7 Guidelines | | Difference (2017 ACC/AHA, But Not JNC7) | |
|--|----------------------------|--|----------------------------|--|---|--|
| Characteristics | Hypertension (N = 5027961) | Recommended Antihypertensive Medication (N = 4266118) | Hypertension (N = 4545976) | Recommended Antihypertensive Medication (N = 3983633) | | Recommended Antihypertensive Medication (N = 282485) |
| History of Hypertension | 75.4% (3793378/5027961) | 78.3% (3339820/4266118) | 83.4% (3793378/4545976) | 80.1% (3189874/3983633) | 0.0% (0/481985) | 53.1% (149946/282485) |
| On Antihypertensive Medications | 66.9% (3365371/5027961) | 78.8% (3363807/4266118) | 73.8% (3353850/4545976) | 84.2% (3355983/3983633) | 2.4% (11521/481985) | 2.8% (7824/282485) |
| Number of BP Measurements Used | | | | | | |
| $Mean \pm SD(N)$ | 2.0±0.1 (5027961) | 2.0±0.1 (4266118) | 2.0±0.1 (4545976) | 2.0±0.1 (3983633) | 2.0±0.1 (481985) | 2.0±0.1 (282485) |
| Median (Q1,Q3) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) | 2.0 (2.0,2.0) |
| Range (Min,Max) | (2.0,6.0) | (2.0,6.0) | (2.0,6.0) | (2.0,6.0) | (2.0,6.0) | (2.0,5.0) |
| Ejection Fraction ≤40 | 9.9% (190324/1919712) | 9.8% (172856/1758731) | 9.6% (176501/1838559) | 9.5% (158348/1659307) | 17.0% (13823/81153) | 14.6% (14508/99424) |
| Ejection Fraction ≤40 among those without hypertension and on antihypertensive meds | 5.1% (12187/238602) | 4.6% (10841/237256) | 0.7% (1541/227956) | 1.5% (3547/229962) | 100.0% (10646/10646) | 100.0% (7294/7294) |

ACC=American College of Cardiology, AHA=American Heart Association; JNC7= Seventh Joint National Committee (JNC7); ASCVD= atherosclerotic cardiovascular disease; CVD= cardiovascular disease; SD=standard deviation; Q=quartile; min=minimum; max=maximum; US=United States, N=number

Table S3. Percentage of U.S. Adults Taking Antihypertensive Medication Who Meet BP Treatment Goal Per 2017 ACC/AHA Guideline, JNC7 Guideline and JNC8 Guideline Based on the 2013–2016 PINNACLE Data, Sensitivity Analysis.

| Subgroups | 2017 ACC/AHA Guideline | JNC7 Guideline | JNC7 Guideline, But Not the 2017 ACC/AHA Guideline | JNC8 Guideline | JNC8 Guideline, But Not the 2017 ACC/AHA Guideline |
|-------------------------------|-------------------------|-------------------------|--|-------------------------|--|
| Overall (N = 2971934) | 41.63% (41.58%, 41.69%) | 64.41% (64.35%, 64.46%) | 22.78% (22.73%, 22.82%) | 79.77% (79.73%, 79.82%) | 38.14% (38.08%, 38.20%) |
| Age group, yrs | | | | | |
| 18-44 (N = 160497) | 39.63% (39.39%, 39.87%) | 67.77% (67.54%, 68.00%) | 28.14% (27.92%, 28.36%) | 73.75% (73.53%, 73.96%) | 34.12% (33.88%, 34.35%) |
| 45-54 (N = 315997) | 37.50% (37.33%, 37.67%) | 64.79% (64.62%, 64.96%) | 27.29% (27.14%, 27.45%) | 73.08% (72.93%, 73.24%) | 35.59% (35.42%, 35.75%) |
| 55-64 (N = 642559) | 39.79% (39.67%, 39.91%) | 64.14% (64.03%, 64.26%) | 24.35% (24.25%, 24.46%) | 77.69% (77.59%, 77.79%) | 37.90% (37.78%, 38.02%) |
| 65-74 (N = 908912) | 41.74% (41.63%, 41.84%) | 63.54% (63.44%, 63.64%) | 21.80% (21.72%, 21.89%) | 81.87% (81.79%, 81.95%) | 40.13% (40.03%, 40.24%) |
| ≥75 (N = 943969) | 44.51% (44.41%, 44.61%) | 64.73% (64.63%, 64.82%) | 20.22% (20.14%, 20.30%) | 82.43% (82.36%, 82.51%) | 37.92% (37.83%, 38.02%) |
| Male (N = 1533143) | 42.73% (42.65%, 42.80%) | 65.40% (65.32%, 65.47%) | 22.67% (22.60%, 22.74%) | 80.38% (80.31%, 80.44%) | 37.65% (37.57%, 37.73%) |
| Female (N = 1436305) | 40.46% (40.38%, 40.54%) | 63.35% (63.28%, 63.43%) | 22.89% (22.82%, 22.96%) | 79.12% (79.06%, 79.19%) | 38.66% (38.58%, 38.74%) |
| Race | | | | | |
| White (N = 1875019) | 42.78% (42.71%, 42.85%) | 65.91% (65.85%, 65.98%) | 23.13% (23.07%, 23.19%) | 81.27% (81.22%, 81.33%) | 38.49% (38.42%, 38.56%) |
| Black (N = 215758) | 30.69% (30.49%, 30.88%) | 51.27% (51.06%, 51.49%) | 20.59% (20.42%, 20.76%) | 67.91% (67.71%, 68.11%) | 37.22% (37.02%, 37.43%) |
| Other (N = 14678) | 41.42% (40.62%, 42.22%) | 60.98% (60.19%, 61.77%) | 19.57% (18.93%, 20.22%) | 76.97% (76.28%, 77.64%) | 35.55% (34.77%, 36.33%) |
| Hispanic (N = 128486) | 39.32% (39.05%, 39.58%) | 59.59% (59.32%, 59.86%) | 20.27% (20.05%, 20.49%) | 76.67% (76.44%, 76.90%) | 37.35% (37.09%, 37.62%) |
| Non-Hispanic (N = 2843448) | 41.74% (41.68%, 41.79%) | 64.63% (64.57%, 64.68%) | 22.89% (22.84%, 22.94%) | 79.91% (79.87%, 79.96%) | 38.18% (38.12%, 38.23%) |
| 10-Year ASCVD Risk categories | | | | | |
| <5% (N = 9209) | 42.87% (41.86%, 43.89%) | 75.76% (74.87%, 76.64%) | 32.89% (31.93%, 33.86%) | 79.72% (78.88%, 80.53%) | 36.84% (35.86%, 37.84%) |
| 5% to <10% (N = 9412) | 37.60% (36.62%, 38.59%) | 68.61% (67.67%, 69.55%) | 31.01% (30.08%, 31.96%) | 78.22% (77.37%, 79.05%) | 40.62% (39.62%, 41.62%) |
| 10% to <20% (N = 13101) | 35.55% (34.73%, 36.37%) | 60.90% (60.06%, 61.74%) | 25.36% (24.61%, 26.11%) | 76.92% (76.19%, 77.64%) | 41.37% (40.53%, 42.22%) |
| ≥20% (N = 13771) | 27.35% (26.61%, 28.11%) | 43.42% (42.59%, 44.25%) | 16.06% (15.45%, 16.69%) | 67.77% (66.98%, 68.55%) | 40.42% (39.60%, 41.24%) |
| History of CVD (N = 1705314) | 44.68% (44.61%, 44.76%) | 65.57% (65.50%, 65.64%) | 20.89% (20.83%, 20.95%) | 81.39% (81.33%, 81.45%) | 36.71% (36.64%, 36.78%) |

ACC=American College of Cardiology, AHA=American Heart Association; JNC7= Seventh Joint National Committee (JNC7); ASCVD= atherosclerotic cardiovascular disease; CVD= cardiovascular disease; US=United States, N=number.

Table S4. Baseline Characteristics of U.S. Adults Taking Antihypertensive Medication Who Meet BP Treatment Goal Per ACC/AHA Guideline, JNC8 Expert Report and JNC7 Guideline Based on the 2013–2016 PINNACLE Data, Sensitivity Analysis.

| Characteristics | ACC/AHA Guideline (N = 1237263) | JNC8 Guideline;∷(N = 2370758) | Difference between ACC/AHA guideline and JNC8 report∰(N = 1133495) | JNC7 Guideline∰(N = 1914176) | Difference between ACC/AHA and JNC7 guidelines∰(N = 676913) |
|-----------------------------------|---------------------------------|-------------------------------|---|---------------------------------|---|
| Age (Years) | | | | | |
| Mean ± SD (N) | 68.2±13.4 (1237263) | 68.0±13.1 (2370758) | 67.8±12.8 (1133495) | 67.4±13.5 (1914176) | 66.0±13.5 (676913) |
| Median (Q1,Q3) | 69.0 (60.0,78.0) | 69.0 (60.0,77.0) | 69.0 (60.0,77.0) | 68.0 (59.0,77.0) | 67.0 (57.0,76.0) |
| Range (Min,Max) | (18.0,100.0) | (18.0,100.0) | (18.0,100.0) | (18.0,100.0) | (18.0,100.0) |
| 18-44 | 5.1% (63607/1237263) | 5.0% (118362/2370758) | 4.8% (54755/1133495) | 5.7% (108770/1914176) | 6.7% (45163/676913) |
| 45-54 | 9.6% (118491/1237263) | 9.7% (230943/2370758) | 9.9% (112452/1133495) | 10.7% (204735/1914176) | 12.7% (86244/676913) |
| 55-64 | 20.7% (255679/1237263) | 21.1% (499186/2370758) | 21.5% (243507/1133495) | 21.5% (412162/1914176) | 23.1% (156483/676913) |
| 65-74 | 30.7% (379337/1237263) | 31.4% (744127/2370758) | 32.2% (364790/1133495) | 30.2% (577516/1914176) | 29.3% (198179/676913) |
| ≥75 | 34.0% (420149/1237263) | 32.8% (778140/2370758) | 31.6% (357991/1133495) | 31.9% (610993/1914176) | 28.2% (190844/676913) |
| Sex | | | | | |
| Male | 53.0% (655057/1236237) | 52.0% (1232284/2368750) | 51.0% (577227/1132513) | 52.4% (1002627/1912588) | 51.4% (347570/676351) |
| Female | 47.0% (581180/1236237) | 48.0% (1136466/2368750) | 49.0% (555286/1132513) | 47.6% (909961/1912588) | 48.6% (328781/676351) |
| Race | | | | | |
| White | 64.8% (802134/1237263) | 64.3% (1523880/2370758) | 63.7% (721746/1133495) | 64.6% (1235904/1914176) | 64.1% (433770/676913) |
| Black | 5.4% (66209/1237263) | 6.2% (146519/2370758) | 7.1% (80310/1133495) | 5.8% (110628/1914176) | 6.6% (44419/676913) |
| Other | 0.5% (6079/1237263) | 0.5% (11297/2370758) | 0.5% (5218/1133495) | 0.5% (8951/1914176) | 0.4% (2872/676913) |
| Missing | 29.3% (362841/1237263) | 29.1% (689062/2370758) | 28.8% (326221/1133495) | 29.2% (558693/1914176) | 28.9% (195852/676913) |
| History of Stroke/TIA | 13.0% (161058/1237263) | 12.8% (304160/2370758) | 12.6% (143102/1133495) | 12.5% (238572/1914176) | 11.5% (77514/676913) |
| History of Stroke | 10.1% (124908/1237263) | 9.9% (235121/2370758) | 9.7% (110213/1133495) | 9.7% (184720/1914176) | 8.8% (59812/676913) |
| History of TIA | 4.1% (50509/1237263) | 4.0% (95730/2370758) | 4.0% (45221/1133495) | 3.9% (74309/1914176) | 3.5% (23800/676913) |
| Coronary Artery Disease | 50.5% (625204/1237263) | 47.8% (1133258/2370758) | 44.8% (508054/1133495) | 47.6% (910715/1914176) | 42.2% (285511/676913) |
| History of MI | 13.5% (166872/1237263) | 12.0% (285585/2370758) | 10.5% (118713/1133495) | 12.4% (237735/1914176) | 10.5% (70863/676913) |
| History of PCI | 18.0% (222978/1237263) | 16.9% (399473/2370758) | 15.6% (176495/1133495) | 16.8% (322516/1914176) | 14.7% (99538/676913) |
| History of CABG | 9.6% (119289/1237263) | 8.7% (206440/2370758) | 7.7% (87151/1133495) | 8.6% (164408/1914176) | 6.7% (45119/676913) |
| Diabetes | 24.5% (303663/1237263) | 22.2% (525846/2370758) | 19.6% (222183/1133495) | 15.9% (303663/1914176) | 0.0% (0/676913) |
| Chronic Kidney Disease | 4.9% (60307/1237263) | 4.2% (99773/2370758) | 3.5% (39466/1133495) | 3.2% (60307/1914176) | 0.0% (0/676913) |
| Heart Failure | 22.2% (274241/1237263) | 19.4% (460751/2370758) | 16.5% (186510/1133495) | 19.8% (378683/1914176) | 15.4% (104442/676913) |
| 10-Year Predicted CVD Risk (%) | | | | | |
| Mean ± SD (N) | 13.5±10.8 (15911) | 14.7±11.4 (34113) | 15.8±11.8 (18202) | 12.9±10.2 (27393) | 12.0±9.1 (11482) |
| Median (Q1,Q3) | 10.8 (5.0,19.3) | 11.9 (5.8,21.1) | 13.0 (6.5,22.6) | 10.3 (4.9,18.5) | 9.6 (4.8,17.4) |
| Range (Min,Max) | (0.1,80.7) | (0.1,80.7) | (0.1,72.2) | (0.1,80.7) | (0.1,63.1) |

| <5% | 24.8% (3948/15911) | 21.5% (7341/34113) | 18.6% (3393/18202) | 25.5% (6977/27393) | 26.4% (3029/11482) |
|----------------|------------------------|-------------------------|------------------------|-------------------------|-----------------------|
| 5% to <10% | 22.2% (3539/15911) | 21.6% (7362/34113) | 21.0% (3823/18202) | 23.6% (6458/27393) | 25.4% (2919/11482) |
| 10% to <20% | 29.3% (4657/15911) | 29.5% (10077/34113) | 29.8% (5420/18202) | 29.1% (7979/27393) | 28.9% (3322/11482) |
| ≥20% | 23.7% (3767/15911) | 27.4% (9333/34113) | 30.6% (5566/18202) | 21.8% (5979/27393) | 19.3% (2212/11482) |
| History of CVD | 61.6% (761986/1237263) | 58.5% (1387969/2370758) | 55.2% (625983/1133495) | 58.4% (1118226/1914176) | 52.6% (356240/676913) |

ACC=American College of Cardiology, AHA=American Heart Association; JNC7= Seventh Joint National Committee (JNC7); ASCVD= atherosclerotic cardiovascular disease; CVD= cardiovascular disease; SD=standard deviation; Q=quartile; min=minimum; max=maximum; TIA=transient ischemic attack; MI=myocardial infarction; PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft; US=United States, N=number.